PeriodontitisNCT07363135
Evaluation of Albumin Platelet-Rich Fibrin Following SRP in Patients With Periodontitis
A study testing Albumin platelet-rich fibrin and Sterile saline (0.9%) in people with Periodontitis and Periodontitis (Stage 3), run by Saglik Bilimleri Universitesi at 1 site in Turkey (Türkiye).
Trial summary
The study aims to investigate whether application of albumin platelet-rich fibrin (Alb-PRF) into the gum pockets after scaling and root planing (SRP) can improve healing in patients with Stage III Grade B periodontitis. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Periodontitis, Periodontitis (Stage 3)
- What is being tested?
- Albumin platelet-rich fibrin and Sterile saline (0.9%)
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 23 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 20 Nov 2024to 1 Feb 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Being diagnosed with Stage 3 Grade B periodontitis
- Being between the ages of 18-65
- Vertical bone defects in two quadrants
Who cannot join
- Smoking
- Having a systemic disease
- Taking any medication
- Being pregnant or breastfeeding
- Having received chemotherapy, radiotherapy or immunosuppressant treatments
- Having received periodontal treatment in the last 6 months•Having used antibiotics in the last 6 months
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Gulhane Faculty of Dentistry, University of Health Sciences, Ankara, Turkey
Ankara, Keçiören, 06010
About this study
Official title: Evaluation of Albumin Platelet-Rich Fibrin Application Following Scaling and Root Planing on Gingival Crevicular Fluid Growth Factors in Patients With Periodontitis
The study aims to investigate whether application of albumin platelet-rich fibrin (Alb-PRF) into the gum pockets after scaling and root planing (SRP) can improve healing in patients with Stage III Grade B periodontitis. Periodontitis is a chronic disease that damages the tissues and bone surrounding the teeth and can lead to tooth loosening or loss if untreated. SRP is the first and most important treatment step, cleaning the tooth surfaces and smoothing the roots to reduce inflammation, but healing is often limited. PRF, made from the patient's own blood, is rich in platelets and growth factors that support tissue repair, and Alb-PRF is a new form that stays longer in the pocket and releases growth factors over time. In this study, 23 patients who meet the inclusion criteria (adults without systemic diseases, not using medications, non-smokers, not pregnant or breastfeeding, and not recently treated for periodontitis) will participate in a split-mouth design, where one side of the mouth receives SRP+ Alb-PRF and the other side receives SRP alone. Clinical measurements, including plaque, gum inflammation, bleeding, pocket depth, gum recession, and attachment levels, will be taken at baseline, 3 months, and 6 months, while X-rays will assess bone defects at baseline and 6 months. Additionally, gingival crevicular fluid (GCF) will be collected from the deepest pockets at baseline and on days 7, 14, and 21 to measure growth factors in the laboratory. Blood from patients will be processed to prepare the albumin-PRF gel, which will be carefully applied to the deep pockets on the test side. The investigators expect that pockets treated with albumin-PRF gel will show greater clinical attachment gain and higher, longer-lasting growth factor levels, potentially leading to improved gum and bone healing compared to SRP alone.
Read the detailed description
The study aims to investigate the effects of applying albumin platelet-rich fibrin (Alb-PRF) into periodontal pockets following scaling and root planing (SRP) on clinical, radiographic, and gingival crevicular fluid (GCF) growth factor parameters in patients with periodontitis. Periodontitis is a chronic inflammatory disease that affects the periodontal ligament and alveolar bone surrounding the teeth, leading to tooth mobility and potential tooth loss if left untreated. SRP represents the initial and most important therapeutic intervention, involving mechanical removal of plaque and calculus, as well as smoothing of root surfaces to reduce inflammation and facilitate healing. While SRP alone can decrease pocket depth and provide some clinical attachment gain, healing is often limited, generally resulting in repair through long junctional epithelium rather than true regeneration. To enhance clinical outcomes and accelerate regeneration, various adjunctive therapies, including local antibiotics, regenerative materials, photodynamic therapy, and laser treatments, have been explored and reported to provide positive effects. In recent years, autologous PRF applied into the periodontal pocket has demonstrated beneficial contributions to both clinical and biochemical parameters, as it is rich in concentrated platelets and alpha granules containing growth factors such as platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and transforming growth factor-beta (TGF-β), which collectively promote cellular proliferation, differentiation, migration, and wound healing. PRF not only delivers these growth factors but also provides a fibrin matrix that acts as a scaffold to support tissue repair. However, the clinical efficacy of PRF is limited by its relatively short duration in the tissue, with effects diminishing approximately 10 days after application, and absorption occurring within a short time frame. To overcome these limitations, a modified approach has been developed in which the upper plasma fraction (platelet poor plasma, PPP) is heat-treated and mixed with the middle PRF layer to produce an Alb-PRF. This material demonstrates prolonged residence in tissue, delayed resorption, and sustained release of growth factors, while also exhibiting improved mechanical properties compared to conventional PRF. In the present study, 23 patients diagnosed with generalized Stage III Grade B periodontitis based on clinical and radiographic examinations will be enrolled. Eligible participants are adults without systemic diseases, not using medications, non-smokers, and not pregnant or breastfeeding, and who have not received periodontal therapy within the past six months. A randomized controlled split-mouth design will be implemented, with one side of the mouth serving as the test site receiving SRP+Alb-PRF, and the contralateral side serving as the control site receiving SRP alone. Clinical periodontal indices, including plaque index, gingival index, bleeding on probing, probing pocket depth, clinical attachment level, and gingival recession, will be recorded at baseline, 3 months, and 6 months. Radiographic assessment of defect depth, percentage of root involvement, and defect angles will be performed at baseline and 6 months. GCF samples will be collected from the deepest pockets at baseline and on days 7, 14, and 21 post-treatment, isolated using periostrips following removal of supragingival plaque, and analyzed for PDGF-BB, VEGF, b-FGF, and TGF-β concentrations using ELISA at the Gülhane Training and Research Hospital Biochemistry Department. Blood for preparation of Alb-PRF will be drawn from the antecubital vein, centrifuged to separate layers, and the upper plasma fraction heated and mixed with injectable PRF using a three-way serum kit to produce the gel, which will then be carefully applied to deep pockets in the test region without overflow. Clinical, radiographic, and biochemical outcomes will be statistically analyzed using SPSS software, employing paired tests such as dependent t-tests, Wilcoxon, and Friedman tests for intra-subject comparisons, with Pearson correlation analysis for continuous variables, and a significance threshold of p<0.05. The sample size of 23 patients (providing 46 test and control sites) was calculated based on previous studies to achieve 95% statistical power. The investigators hypothesized that Alb-PRF application will result in superior clinical attachment gain and prolonged expression of growth factors compared to SRP alone, thus potentially enhancing both soft tissue and alveolar bone regeneration.
- Conditions
- Periodontitis, Periodontitis (Stage 3)
- Being tested
- Albumin platelet-rich fibrin, Sterile saline (0.9%)
- Keywords
- periodontitis, prf, platelet rich-fibrin, Non-surgical periodontal treatment, Albumin prf, platelet-derived growth factor, vascular endothelial growth factor, basic fibroblast growth factor, transforming growth factor-beta
- Medical subject headings
- Periodontitis, Camurati-Engelmann Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Albumin platelet-rich fibrinProcedure or surgery
Application of Alb-PRF to the periodontal pockets in the test sites.
Sterile saline (0.9%)Other
Control sites received a sham intervention consisting of sterile saline solution irrigation into the periodontal pockets, to mimic the procedural aspects of PRF placement without delivering any biologically active material.
| Study group | Role | What they receive |
|---|---|---|
| Test Site | Experimental | Application of Alb-PRF to periodontal pockets in the test sites. Receives: Procedure: Albumin platelet-rich fibrin |
| Control Site | Sham comparator | Control sites received a sham intervention consisting of sterile saline solution irrigation into the periodontal pockets, to mimic the procedural aspects of PRF placement without delivering any biologically active material. Receives: Other: Sterile saline (0.9%) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Probing Pocket Depth (PPD)
Change in probing pocket depth (mm) measured at baseline, 3 months, and 6 months following treatment.
Measured: Baseline, 3 months, and 6 months
Change in Clinical Attachment Level (CAL)
Change in clinical attachment level (mm) measured at baseline, 3 months, and 6 months following treatment.
Measured: Baseline, 3 months, and 6 months
Concentration of PDGF-BB in Gingival Crevicular Fluid
PDGF-BB concentration (pg/mL) measured in gingival crevicular fluid at baseline and on days 7, 14, and 21 following treatment.
Measured: Baseline, Day 7, Day 14, Day 21
Concentration of VEGF in Gingival Crevicular Fluid
VEGF concentration (pg/mL) measured in gingival crevicular fluid at baseline and on days 7, 14, and 21 following treatment.
Measured: Baseline, Day 7, Day 14, Day 21
Concentration of b-FGF in Gingival Crevicular Fluid
b-FGF concentration (pg/mL) measured in gingival crevicular fluid at baseline and on days 7, 14, and 21 following treatment
Measured: Baseline, Day 7, Day 14, Day 21
Concentration of TGF-β in Gingival Crevicular Fluid
TGF-β concentration (pg/mL) measured in gingival crevicular fluid at baseline and on days 7, 14, and 21 following treatment.
Measured: Baseline, Day 7, Day 14, Day 21
Secondary outcomes (7)
Change in Plaque Index Score
Change in plaque index score assessed at baseline, 3 months, and 6 months following treatment.
Measured: Baseline, 3 months, and 6 months
Change in Gingival Index Score
Change in gingival index score assessed using at baseline, 3 months, and 6 months following treatment.
Measured: Baseline, 3 months, and 6 months
Change in Bleeding on Probing Percentage (%)
Change in bleeding on probing expressed as a percentage of bleeding sites assessed at baseline, 3 months, and 6 months following treatmen
Measured: Baseline, 3 months, and 6 months
Change in Gingival Recession (mm)
Change in gingival recession measured in millimeters from the cemento-enamel junction (CEJ) to the gingival margin at baseline, 3 months, and 6 months following treatment
Measured: Baseline, 3 months, and 6 months
Change in Radiographic Bone Defect Depth (mm)
Change in bone defect depth measured on standardized periapical radiographs as the vertical distance from the cemento-enamel junction (CEJ) to the base of the defect at baseline and 6 months following treatment.
Measured: Baseline and 6 months
Change in Radiographic Bone Loss Percentage Relative to Root Length (%)
Change in radiographic bone loss percentage calculated relative to root length. Root length was defined as the distance from the cemento-enamel junction (CEJ) to the point where a line drawn parallel to the long axis of the tooth intersected a horizontal line passing through the root apex, measured at baseline and 6 months.
Measured: Baseline and 6 months
Change in Radiographic Bone Defect Angle (degrees, °)
Change in the radiographic bone defect angle measured on standardized periapical radiographs at baseline and 6 months following treatment. The defect angle was defined as the angle between a line drawn parallel to the long axis of the tooth and a line connecting the cemento-enamel junction (CEJ) to the base of the bone defect.
Measured: Baseline and 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jan 2026
- Study start20 Nov 2024
- Primary completion15 Oct 2025
- Study completion1 Feb 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for PeriodontitisStudies of the same condition, open and under way.
- More trials run by Saglik Bilimleri UniversitesiThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This study utilized a split-mouth, within-subject design rather than a classical crossover or parallel group design. Each subject received both the intervention (Alb-PRF) and control (no Alb-PRF) on different sites of the oral cavity.
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 23 participants (actual)
Sponsor and investigators
- Lead sponsor
- Saglik Bilimleri Universitesi
- Sponsor type
- University, hospital or other
- Collaborators
- The Scientific and Technological Research Council of Turkey
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07363135
- Sponsor's protocol ID
- 2023/248A
- Status last verified
- Nov 2025
- First submitted
- 16 Dec 2025
- Last updated
- 17 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Ozcan E, Ulu Emir B, Avci E, Ozarslanturk S, Bahar SC. Effects of albumin-platelet-rich fibrin as an adjunct to non-surgical periodontal therapy in patients with periodontitis: a randomized controlled clinical trial. BMC Oral Health. 2026 Jun 2. doi: 10.1186/s12903-026-08677-w. Online ahead of print.
PubMed 42231297
Study at a glance
From the registry record, last updated by the sponsor on 17 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Albumin Platelet-Rich Fibrin Application Following Scaling and Root Planing on Gingival Crevicular Fluid Growth Factors in Patients With Periodontitis
- ClinicalTrials.gov ID
- NCT07363135
- Acronym / sponsor ID
- 2023/248A
- Conditions
- Periodontitis, Periodontitis (Stage 3)
- Keywords
- periodontitis, prf, platelet rich-fibrin, Non-surgical periodontal treatment, Albumin prf, platelet-derived growth factor, vascular endothelial growth factor, basic fibroblast growth factor
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 23 participants (actual)
- Lead sponsor
- Saglik Bilimleri UniversitesiUniversity, hospital or other
- Collaborators
- The Scientific and Technological Research Council of Turkey
- Study start
- 20 Nov 2024 (actual)
- Primary completion
- 15 Oct 2025 (actual)
- Study completion
- 1 Feb 2026 (actual)
- First posted
- 23 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study aims to investigate whether application of albumin platelet-rich fibrin (Alb-PRF) into the gum pockets after scaling and root planing (SRP) can improve healing in patients with Stage III Grade B periodontitis. Periodontitis is a chronic disease that damages the tissues and bone surrounding the teeth and can lead to tooth loosening or loss if untreated. SRP is the first and most important treatment step, cleaning the tooth surfaces and smoothing the roots to reduce inflammation, but healing is often limited. PRF, made from the patient's own blood, is rich in platelets and growth factors that support tissue repair, and Alb-PRF is a new form that stays longer in the pocket and releases growth factors over time. In this study, 23 patients who meet the inclusion criteria (adults without systemic diseases, not using medications, non-smokers, not pregnant or breastfeeding, and not recently treated for periodontitis) will participate in a split-mouth design, where one side of the mouth receives SRP+ Alb-PRF and the other side receives SRP alone. Clinical measurements, including plaque, gum inflammation, bleeding, pocket depth, gum recession, and attachment levels, will be taken at baseline, 3 months, and 6 months, while X-rays will assess bone defects at baseline and 6 months. Additionally, gingival crevicular fluid (GCF) will be collected from the deepest pockets at baseline and on days 7, 14, and 21 to measure growth factors in the laboratory. Blood from patients will be processed to prepare the albumin-PRF gel, which will be carefully applied to the deep pockets on the test side. The investigators expect that pockets treated with albumin-PRF gel will show greater clinical attachment gain and higher, longer-lasting growth factor levels, potentially leading to improved gum and bone healing compared to SRP alone.
Detailed description
The study aims to investigate the effects of applying albumin platelet-rich fibrin (Alb-PRF) into periodontal pockets following scaling and root planing (SRP) on clinical, radiographic, and gingival crevicular fluid (GCF) growth factor parameters in patients with periodontitis. Periodontitis is a chronic inflammatory disease that affects the periodontal ligament and alveolar bone surrounding the teeth, leading to tooth mobility and potential tooth loss if left untreated. SRP represents the initial and most important therapeutic intervention, involving mechanical removal of plaque and calculus, as well as smoothing of root surfaces to reduce inflammation and facilitate healing. While SRP alone can decrease pocket depth and provide some clinical attachment gain, healing is often limited, generally resulting in repair through long junctional epithelium rather than true regeneration. To enhance clinical outcomes and accelerate regeneration, various adjunctive therapies, including local antibiotics, regenerative materials, photodynamic therapy, and laser treatments, have been explored and reported to provide positive effects. In recent years, autologous PRF applied into the periodontal pocket has demonstrated beneficial contributions to both clinical and biochemical parameters, as it is rich in concentrated platelets and alpha granules containing growth factors such as platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and transforming growth factor-beta (TGF-β), which collectively promote cellular proliferation, differentiation, migration, and wound healing. PRF not only delivers these growth factors but also provides a fibrin matrix that acts as a scaffold to support tissue repair. However, the clinical efficacy of PRF is limited by its relatively short duration in the tissue, with effects diminishing approximately 10 days after application, and absorption occurring within a short time frame. To overcome these limitations, a modified approach has been developed in which the upper plasma fraction (platelet poor plasma, PPP) is heat-treated and mixed with the middle PRF layer to produce an Alb-PRF. This material demonstrates prolonged residence in tissue, delayed resorption, and sustained release of growth factors, while also exhibiting improved mechanical properties compared to conventional PRF. In the present study, 23 patients diagnosed with generalized Stage III Grade B periodontitis based on clinical and radiographic examinations will be enrolled. Eligible participants are adults without systemic diseases, not using medications, non-smokers, and not pregnant or breastfeeding, and who have not received periodontal therapy within the past six months. A randomized controlled split-mouth design will be implemented, with one side of the mouth serving as the test site receiving SRP+Alb-PRF, and the contralateral side serving as the control site receiving SRP alone. Clinical periodontal indices, including plaque index, gingival index, bleeding on probing, probing pocket depth, clinical attachment level, and gingival recession, will be recorded at baseline, 3 months, and 6 months. Radiographic assessment of defect depth, percentage of root involvement, and defect angles will be performed at baseline and 6 months. GCF samples will be collected from the deepest pockets at baseline and on days 7, 14, and 21 post-treatment, isolated using periostrips following removal of supragingival plaque, and analyzed for PDGF-BB, VEGF, b-FGF, and TGF-β concentrations using ELISA at the Gülhane Training and Research Hospital Biochemistry Department. Blood for preparation of Alb-PRF will be drawn from the antecubital vein, centrifuged to separate layers, and the upper plasma fraction heated and mixed with injectable PRF using a three-way serum kit to produce the gel, which will then be carefully applied to deep pockets in the test region without overflow. Clinical, radiographic, and biochemical outcomes will be statistically analyzed using SPSS software, employing paired tests such as dependent t-tests, Wilcoxon, and Friedman tests for intra-subject comparisons, with Pearson correlation analysis for continuous variables, and a significance threshold of p<0.05. The sample size of 23 patients (providing 46 test and control sites) was calculated based on previous studies to achieve 95% statistical power. The investigators hypothesized that Alb-PRF application will result in superior clinical attachment gain and prolonged expression of growth factors compared to SRP alone, thus potentially enhancing both soft tissue and alveolar bone regeneration.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
- Model description
- This study utilized a split-mouth, within-subject design rather than a classical crossover or parallel group design. Each subject received both the intervention (Alb-PRF) and control (no Alb-PRF) on different sites of the oral cavity.
| Arm | Type | Receives |
|---|---|---|
| Test Site | Experimental | Procedure: Albumin platelet-rich fibrinApplication of Alb-PRF to periodontal pockets in the test sites. |
| Control Site | Sham comparator | Other: Sterile saline (0.9%)Control sites received a sham intervention consisting of sterile saline solution irrigation into the periodontal pockets, to mimic the procedural aspects of PRF placement without delivering any biologically active material. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Being diagnosed with Stage 3 Grade B periodontitis
- Being between the ages of 18-65
- Vertical bone defects in two quadrants
Key exclusion criteria (6 listed)
- Smoking
- Having a systemic disease
- Taking any medication
- Being pregnant or breastfeeding
- Having received chemotherapy, radiotherapy or immunosuppressant treatments
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Albumin platelet-rich fibrinApplication of Alb-PRF to the periodontal pockets in the test sites. | Procedure or surgery | Test Site |
| Sterile saline (0.9%)Control sites received a sham intervention consisting of sterile saline solution irrigation into the periodontal pockets, to mimic the procedural aspects of PRF placement without delivering any biologically active material. | Other | Control Site |
Primary outcome
Change in Probing Pocket Depth (PPD)
Time frame: Baseline, 3 months, and 6 months
Change in probing pocket depth (mm) measured at baseline, 3 months, and 6 months following treatment.
Change in Clinical Attachment Level (CAL)
Time frame: Baseline, 3 months, and 6 months
Change in clinical attachment level (mm) measured at baseline, 3 months, and 6 months following treatment.
Concentration of PDGF-BB in Gingival Crevicular Fluid
Time frame: Baseline, Day 7, Day 14, Day 21
PDGF-BB concentration (pg/mL) measured in gingival crevicular fluid at baseline and on days 7, 14, and 21 following treatment.
Concentration of VEGF in Gingival Crevicular Fluid
Time frame: Baseline, Day 7, Day 14, Day 21
VEGF concentration (pg/mL) measured in gingival crevicular fluid at baseline and on days 7, 14, and 21 following treatment.
Concentration of b-FGF in Gingival Crevicular Fluid
Time frame: Baseline, Day 7, Day 14, Day 21
b-FGF concentration (pg/mL) measured in gingival crevicular fluid at baseline and on days 7, 14, and 21 following treatment
Concentration of TGF-β in Gingival Crevicular Fluid
Time frame: Baseline, Day 7, Day 14, Day 21
TGF-β concentration (pg/mL) measured in gingival crevicular fluid at baseline and on days 7, 14, and 21 following treatment.
7 secondary outcomes
Change in Plaque Index Score
Time frame: Baseline, 3 months, and 6 months
Change in Gingival Index Score
Time frame: Baseline, 3 months, and 6 months
Change in Bleeding on Probing Percentage (%)
Time frame: Baseline, 3 months, and 6 months
Change in Gingival Recession (mm)
Time frame: Baseline, 3 months, and 6 months
Change in Radiographic Bone Defect Depth (mm)
Time frame: Baseline and 6 months
Change in Radiographic Bone Loss Percentage Relative to Root Length (%)
Time frame: Baseline and 6 months
Change in Radiographic Bone Defect Angle (degrees, °)
Time frame: Baseline and 6 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Feb 2026.
- Derived from this study: PubMed 42231297Ozcan E, Ulu Emir B, Avci E, Ozarslanturk S, Bahar SC. Effects of albumin-platelet-rich fibrin as an adjunct to non-surgical periodontal therapy in patients with periodontitis: a randomized controlled clinical trial. BMC Oral Health. 2026 Jun 2. doi: 10.1186/s12903-026-08677-w. Online ahead of print.
Related trials for Periodontitis
Recruiting
Effect of Cryotherapeutic and Nanotherapeutic Sodium Hypochlorite on Post-Operative Endodontic Pain.
Symptomatic Irreversible Pulpitis, Symptomatic Apical Periodontitis
Active, not recruitingObservational study
A Retrospective Comparative Evaluation of Omega-3 and Resveratrol Supplementation in Patients With Periodontitis
Periodontitis
Recruiting
Probiotics Versus Antibiotics as an Adjuvant to Non-surgical Periodontal Treatment Among Smokers With Stage II, Grade B Periodontitis
Probiotics, Antibiotics
Recruiting
Effects of Different Activation Techniques on Antimicrobial Photodynamic Therapy in Apical Periodontitis
Apical Periodontitis, Endodontic Retreatment
Recruiting
Ozone Gel Versus Chlorohexidine Gel as an Adjunct to Non-Surgical Treatment of Stage II Periodontitis Grade B Among Smokers Patients
Ozone Gel, Chlorohexidine Gel
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Albumin platelet-rich fibrin and Sterile saline (0.9%) in people with Periodontitis and Periodontitis (Stage 3), run by Saglik Bilimleri Universitesi at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Probing Pocket Depth (PPD) (time frame: Baseline, 3 months, and 6 months). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07363135, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Feb 2026.